By Chris Wack
Hims & Hers Health shares reached another all-time high after the company said it plans to introduce at-home lab testing through its platform after buying an at-home testing facility, Sigmund NJ.
The stock was up 15% to $67.28 in Tuesday morning trading, after touching an all-time high of $70.50. Shares of Hims & Hers have been setting new all-time highs in the past month, and have more than doubled in price in that time. The stock has risen more than seven-fold in the last year.
The health and wellness platform said buying Sigmund NJ, marketed as Trybe Labs, will allow it to support at-home blood draws and more comprehensive whole body testing.
The tests will allow customers to access a wider amount of data and biomarkers that can help identify the risk of disease before it develops, allowing for more precise clinical decision-making, Hims & Hers said.
Hims & Hers funded the acquisition through cash on hand. The acquisition is complete, and Hims & Hers expects to roll out at-home testing to customers in the next year.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 19, 2025 11:03 ET (16:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。